Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UCART20x22 · 1 trial · 1 indication
Incidence, nature and severity of adverse events and serious adverse events in relation to UCART20x22 and/or lymphodepletion
| Arm | Type | Description |
|---|---|---|
| Dose finding part | EXPERIMENTAL | UCART20x22 tested at several dose levels until the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) is identified. Dose expansion part: UCART20x22 administered at the RP2D determined during the dose finding part |
| Name | Type | Description |
|---|---|---|
| UCART20x22 | BIOLOGICAL | Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen |
| CLLS52 | BIOLOGICAL | A monoclonal antibody that recognizes a CD52 antigen |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Relapsed or refractory (R/R) mature B-NHL per 2016 WHO criteria and positive for CD20 and/or CD22 * Subjects with NHL subtypes defined by WHO: * Dose-Finding Part: R/R mature B-NHL (except chronic lymphoc...
UCART20x22 is an investigational monoclonal antibody being developed for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL). It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in a single active clinical trial.
UCART20x22 targets the CD20 and CD22 antigens, which are expressed on B cells. By binding to these targets, the drug is designed to direct the immune system against malignant B cells in B-cell Non-Hodgkin Lymphoma. This dual-targeting approach is being evaluated in early-phase clinical trials.
UCART20x22 is being developed by Cellectis S.A., a biopharmaceutical company listed on the stock exchange under the ticker CLLS. The company is conducting clinical trials for this investigational therapy in patients with B-cell Non-Hodgkin Lymphoma.
UCART20x22 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received FDA approval. The ongoing Phase 1 trial is recruiting participants to evaluate the safety and preliminary efficacy of UCART20x22 in B-cell Non-Hodgkin Lymphoma.
UCART20x22 is being evaluated in one active clinical trial with the identifier NCT05607420. This Phase 1 study is recruiting 80 participants with B-cell Non-Hodgkin Lymphoma at sites in the United States, France, and Spain. The trial is open to adults aged 18 years and older.
UCART20x22 is a distinct investigational drug developed by Cellectis S.A. It is not known to be the same as any other approved or investigational therapy. Its unique mechanism targets both CD20 and CD22, setting it apart from single-target B-cell lymphoma treatments.